In the absence of a lab test, identifying culprit drugs in patients with SJS/TEN is difficult, and patients take on average six medications at the time of their reaction, the authors of a new study write.
The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost-effectively identify those at risk who could potentially receive it.
New research goes "a step further" than previous studies by revealing a population of T cells in multiple sclerosis that may be responding directly to EBV during active viral disease, experts say.